The Ulcerative colitis - ustekinumab as a new biologic therapy, review 2024
DOI:
https://doi.org/10.12775/QS.2024.17.53670Keywords
ustekinumab, interleukin 12/23 inhibitor, inflammatory bowel disease, ulcerative colitisAbstract
Biologic agents have significantly transformed the therapeutic approach to ulcerative colitis. Anti-tumor necrosis factor (TNF) agents were the pioneering biologic drugs introduced to induce and maintain remission in this inflammatory bowel disease. Recently, ustekinumab, another biologic option, has been approved for the treatment of moderate-to-severe ulcerative colitis. Ustekinumab demonstrates a favorable clinical efficacy and safety profile for the treatment of moderately to severely active ulcerative colitis. As the first biologic agent to target the IL-12/IL-23 pathways, ustekinumab represents a viable therapeutic option, particularly following the failure of other biologics such as anti-tumor necrosis factor-α (TNF-α) antagonists and anti-α4ß7 integrin antagonists
References
OrdaÌs I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. The Lancet. 2012 Nov 3;380(9853):1606–19.
Segal JP, Jean-Frédéric LeBlanc A, Hart AL. Ulcerative colitis: an update. Clinical Medicine [Internet]. 2021 Mar 1 [cited 2024 Apr 29];21(2):135. Available from: /pmc/articles/PMC8002778/
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet [Internet]. 2017 Apr 4 [cited 2024 Apr 29];389(10080):1756. Available from: /pmc/articles/PMC6487890/
Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. Journal of Clinical Medicine 2020, Vol 9, Page 94 [Internet]. 2019 Dec 30 [cited 2024 Apr 29];9(1):94. Available from: https://www.mdpi.com/2077-0383/9/1/94/htm
Cosnes J, Gowerrousseau C, Seksik P, Cortot A. Epidemiology and Natural History of Inflammatory Bowel Diseases. Gastroenterology. 2011 May 1;140(6):1785-1794.e4.
Feuerstein JD, Cheifetz AS. Ulcerative Colitis: Epidemiology, Diagnosis, and Management. Mayo Clin Proc. 2014 Nov 1;89(11):1553–63.
Kucharzik T, Koletzko S, Kannengießer K, Dignaß A. Ulcerative Colitis—Diagnostic and Therapeutic Algorithms. Dtsch Arztebl Int [Internet]. 2020 Aug 17 [cited 2024 Apr 29];117(33–34):564. Available from: /pmc/articles/PMC8171548/
Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet [Internet]. 2023 Aug 12 [cited 2024 May 26];402(10401):571–84. Available from: https://pubmed.ncbi.nlm.nih.gov/37573077/
Gawron-Kiszka M, Hartleb M. Wrzodziejące zapalenie jelita grubego – jak rozpoznawać i leczyć według aktualnych wytycznych? Lekarz POZ. 2023;9(2):116–21.
Glinkowski S, Marcinkowska D. Ulcerative colitis: assessment of disease activity based on contemporary scales. Nowa Medycyna. 2018 Aug 8;25(3).
Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. JAMA [Internet]. 2023 Sep 12 [cited 2024 May 18];330(10):951–65. Available from: https://pubmed.ncbi.nlm.nih.gov/37698559/
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut [Internet]. 2019 Dec 1 [cited 2024 May 27];68(Suppl 3):s1–106. Available from: https://pubmed.ncbi.nlm.nih.gov/31562236/
Fukuda T, Naganuma M, Kanai T. Current new challenges in the management of ulcerative colitis. Intest Res [Internet]. 2019 Jan 1 [cited 2024 Apr 29];17(1):36. Available from: /pmc/articles/PMC6361009/
Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, et al. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol [Internet]. 2017 Mar 4 [cited 2024 Apr 29];13(3):223–33. Available from: https://www.tandfonline.com/doi/abs/10.1080/1744666X.2017.1243468
Mshimesh BAR. Studying activity and toxicity of different TNF-alpha inhibitors in controlling patients with active ulcerative colitis. J Appl Pharm Sci [Internet]. 2019 Feb 22 [cited 2024 Apr 29];9,(2):087–96. Available from: https://japsonline.com/abstract.php?article_id=2845&sts=2
Fausel R, Afzali A, Afzali A. Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag [Internet]. 2015 [cited 2024 Apr 29];11:63–72. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=dtcr20
Bhattacharya A, Osterman MT. Biologic Therapy for Ulcerative Colitis. Gastroenterol Clin North Am [Internet]. 2020 Dec 1 [cited 2024 May 26];49(4):717–29. Available from: https://pubmed.ncbi.nlm.nih.gov/33121691/
Biancone L, Ardizzone S, Armuzzi A, Castiglione F, D’incà R, Danese S, et al. Ustekinumab for treating ulcerative colitis: an expert opinion. Expert Opin Biol Ther [Internet]. 2020 [cited 2024 Apr 29];20(11):1321–9. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=iebt20
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med [Internet]. 2005 Dec 8 [cited 2024 Apr 29];353(23):2462–76. Available from: https://pubmed.ncbi.nlm.nih.gov/16339095/
Fiorino G, Allocca M, Correale C, Roda G, Furfaro F, Loy L, et al. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. Expert Opin Biol Ther [Internet]. 2020 Apr 2 [cited 2024 Apr 29];20(4):421–7. Available from: https://pubmed.ncbi.nlm.nih.gov/32027523/
Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context [Internet]. 2019 [cited 2024 Apr 29];8. Available from: /pmc/articles/PMC6490072/
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, Macintosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: The CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33.
Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann Intern Med. 2007 Jun 5;146(12):829–38.
Fiorino G, Allocca M, Correale C, Roda G, Furfaro F, Loy L, et al. Expert Opinion on Biological Therapy Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. 2020 [cited 2024 May 27]; Available from: https://www.tandfonline.com/action/journalInformation?journalCode=iebt20
Pugliese D, Privitera G, Fiorani M, Parisio L, Calvez V, Papa A, et al. Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. Therap Adv Gastroenterol [Internet]. 2022 [cited 2024 May 27];15. Available from: https://pubmed.ncbi.nlm.nih.gov/35721840/
Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol [Internet]. 2023 Jul 1 [cited 2024 May 27];20(7):433–46. Available from: https://pubmed.ncbi.nlm.nih.gov/37069321/
Korta A, Kula J, Gomułka K. The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease. International Journal of Molecular Sciences 2023, Vol 24, Page 10172 [Internet]. 2023 Jun 15 [cited 2024 Apr 29];24(12):10172. Available from: https://www.mdpi.com/1422-0067/24/12/10172/htm
Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol [Internet]. 2023 Jul 1 [cited 2024 Apr 29];20(7):433–46. Available from: https://mayoclinic.elsevierpure.com/en/publications/il-12-and-il-23-pathway-inhibition-in-inflammatory-bowel-disease
Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos CC. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn’s disease. World J Gastroenterol [Internet]. 2018 Sep 9 [cited 2024 Apr 29];24(36):4093. Available from: /pmc/articles/PMC6158482/
Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med [Internet]. 2019 Sep 26 [cited 2024 May 18];381(13):1201–14. Available from: https://pubmed.ncbi.nlm.nih.gov/31553833/
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med [Internet]. 2016 Nov 17 [cited 2024 May 18];375(20):1946–60. Available from: https://pubmed.ncbi.nlm.nih.gov/27959607/
Amiot A, Filippi J, Abitbol | Vered, Cadiot G, Laharie D, Serrero M, et al. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther [Internet]. 2020 [cited 2024 May 22];51:1039–46. Available from: https://onlinelibrary.wiley.com/doi/10.1111/apt.15717
Chaparro M, Garre A, Iborra M, Sierra-Ausín M, Barreiro-De Acosta M, Fernández-Clotet A, et al. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. J Crohns Colitis [Internet]. 2021 Nov 8 [cited 2024 May 22];15(11):1846–51. Available from: https://dx.doi.org/10.1093/ecco-jcc/jjab070
Fumery M, Filippi J, Abitbol V, Biron A, Laharie D, Serrero M, et al. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther [Internet]. 2021 Oct 1 [cited 2024 May 26];54(7):944–51. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/apt.16544
Fumery M, Filippi J, Abitbol V, Biron A, Laharie D, Serrero M, et al. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther [Internet]. 2021 Oct 1 [cited 2024 May 26];54(7):944–51. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/apt.16544
Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. UEG Journal [Internet]. 2020 Feb 1 [cited 2024 May 26];8(1):91–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1177/2050640619895361
Wilcock A, Howard BMedSci P, Carone L, Oxberry SG, Twycross R, Charlesworth S, et al. Therapeutic Reviews Series Co-Editors: Spironolactone AHFS 24:32.20. J Pain Symptom Manage [Internet]. 2017 [cited 2024 May 25];53(2). Available from: http://dx.doi.org/10.1016/j.jpainsymman.2016.12.320
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zuzanna Felińska, Julia Silldorff, Tomasz Fura, Marcin Dudek, Radosław Zaucha, Oliwia Iszczuk, Stanisław Anczyk, Magdalena Gajkiewicz, Małgorzata Zając
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 85
Number of citations: 0
